Outsourced AstraZeneca blockade not an issue for local COVID vaccine rollout

EU's decision to block 250,000 doses of AstraZeneca vaccine to Australia not an issue for covid vaccine rollout thanks to CSL local production

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Countries are holding on tight to their locally produced COVID-19 vaccines. As reported by ABC News, Italy and the European Union pulled the handbrake on the 250,000 AstraZeneca Plc (LSE: AZN) doses bound for Aussie shores. Australian politicians have stated that this is not an issue for our COVID-19 vaccine rollout.

As countries globally rush to get their hands on an approved vaccine, tensions have developed. Considering it is a potential ticket to returned economic growth, some are prioritising their own jurisdictions first and foremost.

CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

Not an issue for our vaccine rollout

Australian Health Minister Greg Hunt remarked that this decision by the EU would not impact Australia's COVID vaccine rollout:

This is one shipment from one country. This shipment was not factored into our distribution plan for the coming weeks. Domestic production starts with 1 million per week of deliveries from late March and is on track.

NSW Premier Gladys Berejiklian commented on the news this morning, emphasising the critical nature of local production:

I think what it demonstrates is the importance of us having a local supply. In the future, there will be supply issues. You need lots of jabs to be vaccinated properly, and therefore it's really important for us to be able to have our local supply.

The local supply these ministers refer to is coming from Australian-based CSL Ltd (ASX: CSL). Despite the emphasised importance of its operations this morning, the CSL share price is trending 2.6% lower. The biotech giant has now fallen for four consecutive sessions, erasing 8% in 4 days.

Domestic production of the AstraZeneca vaccine by CSL was expected to begin in early March. The company's production is anticipated to yield around 1 million doses per week by the end of March.

Ironic timing as first AstraZeneca vaccine administered

The EU's decision to block the 250,000 vaccines comes at an ironic time, as the first AstraZeneca dose was administered in Australia today.

An estimated 40 frontline staff at the Murray Bridge Hospital in South Australia will have received the vaccine by the end of the day.

Premier Berejiklian also mentioned that she believed media coverage should pivot to reporting on the number of vaccines administered rather than the number of new cases.

Furthermore, with the COVID vaccine rollout underway, the premier urged for the reopening of borders. Otherwise, she said, Australia could be left in the dust economically.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Business women working from home with stock market chart showing per cent change on her laptop screen.
Share Market News

The war in Iran has inspired an unexpected ASX 200 market trend

A strong theme is apparent in recent trading data -- and it's not what you think.

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Wednesday

Here's what to expect on the benchmark index today.

Read more »

View of a mine site.
Share Market News

Up 450% in a year — why this ASX gold stock could soar further

Strong drilling, solid funding, and scale potential are exciting investors.

Read more »

Happy young woman saving money in a piggy bank.
Broker Notes

Up more than 17% since January, should you buy CBA shares today?

A leading analyst delivers his forecast for CBA’s fast-rising shares.

Read more »

A woman leans forward with her hands shielding her eyes as if she is looking intently for something.
Growth Shares

5 ASX shares I'd buy with $5,000 today

These shares are on my radar right now.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Opinions

Is that the end of the ASX share market crash?

The stock market looks like it has started to recover.

Read more »

Frustrated man at computer desk.
Share Market News

5 most traded ASX 200 shares since the war began

Only one of them is an energy stock.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Opinions

3 reasons to buy NAB shares today

Here's why I think the ASX bank stock is still a buy.

Read more »